Acquired reactive perforating collagenosis secondary to Cabozantinib: A case report and literature review
2024

Case Report of Skin Condition Linked to Cabozantinib

Sample size: 1 publication Evidence: low

Author Information

Author(s): Rehan Zahra, Haner Andrea, Taleb Amina, Ikeri Nzechukwu, Hardin Jori

Primary Institution: Cumming School of Medicine, University of Calgary

Hypothesis

Is acquired reactive perforating collagenosis (ARPC) associated with Cabozantinib treatment?

Conclusion

The study presents a novel case of ARPC linked to Cabozantinib therapy, showing partial improvement with topical treatment after stopping the medication.

Supporting Evidence

  • ARPC is a rare skin condition often linked to systemic diseases and certain medications.
  • The patient had a history of diabetes and developed ulcers after starting Cabozantinib.
  • Topical treatments were initiated after stopping Cabozantinib, leading to gradual improvement.

Takeaway

A woman developed a skin problem after taking a cancer drug called Cabozantinib, but her condition got better when she stopped the drug and used a special cream.

Methodology

Case report detailing the patient's history, symptoms, treatment, and follow-up.

Limitations

The findings are based on a single case report, limiting generalizability.

Participant Demographics

60-year-old female with metastatic clear cell carcinoma and a history of diabetes.

Digital Object Identifier (DOI)

10.1177/2050313X241304961

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication